Eton Pharmaceuticals (ETON) Income towards Parent Company (2019 - 2025)
Historic Income towards Parent Company for Eton Pharmaceuticals (ETON) over the last 7 years, with Q3 2025 value amounting to -$1.9 million.
- Eton Pharmaceuticals' Income towards Parent Company fell 40733.65% to -$1.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$6.7 million, marking a year-over-year decrease of 2191.21%. This contributed to the annual value of -$3.8 million for FY2024, which is 30844.02% down from last year.
- Latest data reveals that Eton Pharmaceuticals reported Income towards Parent Company of -$1.9 million as of Q3 2025, which was down 40733.65% from -$2.6 million recorded in Q2 2025.
- Eton Pharmaceuticals' Income towards Parent Company's 5-year high stood at $5.1 million during Q1 2021, with a 5-year trough of -$6.1 million in Q3 2021.
- Moreover, its 5-year median value for Income towards Parent Company was -$1.6 million (2025), whereas its average is -$1.1 million.
- Per our database at Business Quant, Eton Pharmaceuticals' Income towards Parent Company surged by 39261.87% in 2023 and then tumbled by 40733.65% in 2025.
- Eton Pharmaceuticals' Income towards Parent Company (Quarter) stood at $1.0 million in 2021, then decreased by 12.22% to $912000.0 in 2022, then crashed by 347.37% to -$2.3 million in 2023, then soared by 73.49% to -$598000.0 in 2024, then tumbled by 222.24% to -$1.9 million in 2025.
- Its Income towards Parent Company stands at -$1.9 million for Q3 2025, versus -$2.6 million for Q2 2025 and -$1.6 million for Q1 2025.